Galderma Showcases Latest Aesthetic Portfolio Data at IMCAS 2025, Highlighting Relfydess and Restylane Advances

Galderma is preparing to showcase significant advances across its aesthetic medicine portfolio at the upcoming International Master Course on Aging Science (IMCAS) World 2025, scheduled for January 30 – February 1 in Paris, France. The company will present comprehensive data through ten research e-posters, highlighting the differentiation of its injectable aesthetic products.

New Long-term Data Reinforces Relfydess Efficacy

The phase IIIb RELAX study results will reveal long-term aesthetic improvements and patient satisfaction over 12 months following single-dose Relfydess treatment for moderate-to-severe frown lines. The data builds on previous findings from the READY clinical trial program, which demonstrated rapid onset of action in up to 39% of patients from day one, with effects lasting up to six months in 75% of patients for both frown lines and crow's feet.

A significant pooled post-hoc analysis from the READY-1-3 trials, encompassing more than 1,700 patients, confirms Relfydess's efficacy across diverse skin types, ethnicities, and races. Additional research validates the role of Galderma's proprietary PEARL Technology in maintaining molecule integrity, with no neutralizing antibody formation observed throughout the phase III program.

Advancing Regenerative Aesthetics with Sculptra

New research data reinforces Sculptra's position as a pioneering regenerative biostimulator, demonstrating its effects across all three skin layers. Studies indicate Sculptra's ability to stimulate key skin components, including collagen, elastin, and adipose tissue, while maintaining a favorable safety profile. A comparative study revealed enhanced outcomes when combining Sculptra with Alastin for midface treatments, showing improved aging skin results and patient satisfaction.

Restylane Portfolio Demonstrates Natural-Looking Results

Pooled data from three Galderma studies highlights how Restylane Refyne and Restylane Defyne enhance attractiveness while preserving natural facial expressions. The latest addition to the portfolio, Restylane SHAYPE, powered by NASHA HD Technology, demonstrates superior gel strength and firmness among commonly used HA fillers, making it particularly effective for lower face shaping.

Comprehensive Educational Program

The congress will feature multiple educational initiatives, including:

• Three scientific symposia
• A specialized Masterclass
• Five Meet the Expert sessions
• An interactive booth focusing on Relfydess

A notable symposium, "Go beyond with Relfydess: Step into the future," will showcase clinical performance and include live injection demonstrations on January 31. The Galderma Aesthetic Injector Network (GAIN), celebrating its 10th anniversary, will host additional educational sessions focusing on treatment prioritization and scientific innovation.

The comprehensive program reflects Galderma's commitment to advancing dermatological science while providing practical education for healthcare professionals. The company's extensive presence at IMCAS 2025 underscores its position as a leader in dermatology, bringing together scientific innovation with clinical expertise.